These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 31529940)
1. The Roll-out of Child-friendly Fixed-dose Combination TB Formulations in High-TB-Burden Countries: A Case Study of STEP-TB. Faust L; Abdi K; Davis K; He C; Mehrotra C; Stibolt E J Epidemiol Glob Health; 2019 Sep; 9(3):210-216. PubMed ID: 31529940 [TBL] [Abstract][Full Text] [Related]
3. Fixed-dose combination drugs for tuberculosis: application in standardised treatment regimens. Blomberg B; Fourie B Drugs; 2003; 63(6):535-53. PubMed ID: 12656652 [TBL] [Abstract][Full Text] [Related]
4. Availability of quality fixed-dose combinations for the treatment of tuberculosis: what can we learn from studying the World Health Organization's vaccine model? Blomberg B; Kitler ME; Milstien J; Dellepiane N; Fanning A; Norval PY; Spinaci S Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S371-80; discussion S381-7. PubMed ID: 10593721 [TBL] [Abstract][Full Text] [Related]
5. Implementation of fixed-dose combinations in tuberculosis control: outline of responsibilities. Chaulet P Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S353-7; discussion S381-7. PubMed ID: 10593717 [TBL] [Abstract][Full Text] [Related]
6. Pediatric TB: issues related to current and future treatment options. Marais BJ; Schaaf HS; Donald PR Future Microbiol; 2009 Aug; 4(6):661-75. PubMed ID: 19659423 [TBL] [Abstract][Full Text] [Related]
7. Treatment of childhood tuberculosis in India. Swaminathan S; Sachdeva KS Int J Tuberc Lung Dis; 2015 Dec; 19 Suppl 1():43-46. PubMed ID: 26564540 [TBL] [Abstract][Full Text] [Related]
9. Size and usage patterns of private TB drug markets in the high burden countries. Wells WA; Ge CF; Patel N; Oh T; Gardiner E; Kimerling ME PLoS One; 2011 May; 6(5):e18964. PubMed ID: 21573227 [TBL] [Abstract][Full Text] [Related]
10. Pediatric Tuberculosis in Italian Children: Epidemiological and Clinical Data from the Italian Register of Pediatric Tuberculosis. Galli L; Lancella L; Tersigni C; Venturini E; Chiappini E; Bergamini BM; Codifava M; Venturelli C; Tosetti G; Marabotto C; Cursi L; Boccuzzi E; Garazzino S; Tovo PA; Pinon M; Le Serre D; Castiglioni L; Lo Vecchio A; Guarino A; Bruzzese E; Losurdo G; Castagnola E; Bossi G; Marseglia GL; Esposito S; Bosis S; Grandolfo R; Fiorito V; Valentini P; Buonsenso D; Domenici R; Montesanti M; Salvini FM; Riva E; Dodi I; Maschio F; Abbagnato L; Fiumana E; Fornabaio C; Ballista P; Portelli V; Bottone G; Palladino N; Valenzise M; Vecchi B; Di Gangi M; Lupi C; Villani A; de Martino M Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27322255 [TBL] [Abstract][Full Text] [Related]
11. Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs. Clemens DL; Lee BY; Silva A; Dillon BJ; Masleša-Galić S; Nava S; Ding X; Ho CM; Horwitz MA PLoS One; 2019; 14(5):e0215607. PubMed ID: 31075149 [TBL] [Abstract][Full Text] [Related]
12. The procurement landscape of pediatric tuberculosis treatment: a Global Drug Facility perspective. Scott C; Gardiner E; de Lucia A Int J Tuberc Lung Dis; 2015 Dec; 19 Suppl 1():17-22. PubMed ID: 26564536 [TBL] [Abstract][Full Text] [Related]
13. Tuberculosis drug issues: prices, fixed-dose combination products and second-line drugs. Laing RO; McGoldrick KM Int J Tuberc Lung Dis; 2000 Dec; 4(12 Suppl 2):S194-207. PubMed ID: 11144553 [TBL] [Abstract][Full Text] [Related]
14. Evidence for promoting fixed-dose combination drugs in tuberculosis treatment and control: a review. Monedero I; Caminero JA Int J Tuberc Lung Dis; 2011 Apr; 15(4):433-9. PubMed ID: 21396199 [TBL] [Abstract][Full Text] [Related]